Cell transplantation for cardiac regeneration: where do we stand?

Bos, Ewout J. van den; Giessen, Wim J. van der; Duncker, Dirk J.

doi:10.1007/bf03086124

Cited by 10 publications

(6 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cell transplantation therapies for organ function restoration and tissue regeneration have been developed utilizing adult cells, adult stem cells, and iPSCs [159][160][161][162]. Similar to organ transplantation, adult cell transplantation has been used to substitute for a lack of native organ function.…”

Section: Cell Transplantationmentioning

confidence: 99%

“…Recognizing what part or parts of an organ are most vital to its function, such as the islet cells for the pancreas, are critical for engineering functional whole organs. Adult stem cells and iPSCs have both been used to regenerate cells and damaged tissue via injection [160,161]. Stem cells are transplanted with the intention of using the microenvironmental cues of the surrounding tissue to induce differentiation of the stem cells into the same type of cell as the tissue they are injected in [164].…”

Section: Cell Transplantationmentioning

confidence: 99%

“…Stem cells are transplanted with the intention of using the microenvironmental cues of the surrounding tissue to induce differentiation of the stem cells into the same type of cell as the tissue they are injected in [164]. For instance, myoblasts have been injected into a site of myocardial infarction in several animal models, with transplantation being shown to improve the heart structure, tissue mechanics, and overall functioning [160]. The promising results of stem cell transplantation for tissue regeneration provide valuable insight into the role that the microenvironment of native ECM can have on cell functions and can be translated into growing cells for whole organ engineering.…”

Section: Cell Transplantationmentioning

confidence: 99%

See 2 more Smart Citations

Whole Organ Engineering: Approaches, Challenges, and Future Directions

et al. 2020

View full text Add to dashboard Cite

End-stage organ failure remains a leading cause of morbidity and mortality across the globe. The only curative treatment option currently available for patients diagnosed with end-stage organ failure is organ transplantation. However, due to a critical shortage of organs, only a fraction of these patients are able to receive a viable organ transplantation. Those patients fortunate enough to receive a transplant must then be subjected to a lifelong regimen of immunosuppressant drugs. The concept of whole organ engineering offers a promising alternative to organ transplantation that overcomes these limitations. Organ engineering is a discipline that merges developmental biology, anatomy, physiology, and cellular interactions with enabling technologies such as advanced biomaterials and biofabrication to create bioartificial organs that recapitulate native organs in vivo. There have been numerous developments in bioengineering of whole organs over the past two decades. Key technological advancements include (1) methods of whole organ decellularization and recellularization, (2) three-dimensional bioprinting, (3) advanced stem cell technologies, and (4) the ability to genetically modify tissues and cells. These advancements give hope that organ engineering will become a commercial reality in the next decade. In this review article, we describe the foundational principles of whole organ engineering, discuss key technological advances, and provide an overview of current limitations and future directions.

show abstract

Section: Cell Transplantationmentioning

confidence: 99%

Section: Cell Transplantationmentioning

confidence: 99%

Section: Cell Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Whole Organ Engineering: Approaches, Challenges, and Future Directions

et al. 2020

View full text Add to dashboard Cite

show abstract

“…inducing angiogenesis, inhibiting apoptosis, and enhancing scar tissue formation, or possibly by myocardial regeneration. 5,6 BMMC therapy: from experimental studies to clinical trials In 2001, Orlic et al reported that subsets of BMMCs are capable of replacing infarcted myocardium and improve ventricular function after AMI in mice. 7 Moreover, a study by Quaini et al, investigating sex-mismatched transplanted hearts, demonstrated migration of cells from the recipient to the donor heart.…”

Section: Introductionmentioning

confidence: 99%

Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results

Laan

Hirsch

Nijveldt

et al. 2008

NHJL

Self Cite

View full text Add to dashboard Cite

During the last decennium, the role of bone marrow mononuclear cells (BMMC) has been underscored in the healing process after acute myocardial infarction (AMI). Although these cells improve left ventricular recovery after AMI in experimental studies, results from large-scale randomised trials investigating BMMC therapy in patients with AMI have shown contradictory results. To address this issue the HEBE study was designed, a multicentre, randomised trial, evaluating the effects of intracoronary infusion of BMMCs and the effects of intracoronary infusion of peripheral blood mononuclear cells after primary percutaneous coronary intervention. The primary endpoint of the HEBE trial is the change in regional myocardial function in dysfunctional segments at four months relative to baseline, based on segmental analysis as measured by magnetic resonance imaging. The results from the HEBE trial will provide detailed information about the effects of intracoronary BMMC therapy on post-infarct left ventricular recovery. In addition, further analysis of the data and material obtained may provide important mechanistic insights into the contribution of BMMCs to natural recovery from AMI as well as the response to cell therapy. This may significantly contribute to the development of improved cell-based therapies, aiming at optimising post-infarct recovery and preventing heart failure. I n t e r u n i v e r s i t y C a r d i o l o g y I n s t i t u t e o f t h e N e t h e r l a n d s 436

show abstract

“…Subsequent studies have mainly used bone marrow (BM)-derived cells, either the whole mononuclear fraction or selected cell sub-populations. 3 The overall impression is that most clinical studies, some of which include large numbers of controls, have reported benefits to patients, often with a significant long-term improvement of their clinical state. 4 …”

mentioning

confidence: 99%

Cardiac and renal cell therapies: similarities and differences

Takiya

Borojević

2011

Kidney International Supplements

View full text Add to dashboard Cite

Patients with terminal cardiac or renal disease have few therapeutic options besides organ transplantation. Optimally, cell therapies would be used both in acute and chronic stages of such diseases. In the injured myocardium, the main therapeutic goal is reestablishment of adequate perfusion and cardiac output. This can be achieved by stem cell (SC) infusions, and currently several clinical trials have provided promising results. Considering the heart's low intrinsic capacity for regeneration and its paucity of resident cardiac SCs, we believe that induction of angiogenesis must be the primary goal, thereby promoting activation of resident SCs as well as mobilization of perivascular mesenchymal SCs that can mediate myocardial regeneration. Renal tissue, in contrast to the myocardium, has a high intrinsic capacity to respond to injuries and thus repair itself. Infusion of bone marrow (BM) cells or of their sub-populations protects the injured renal tissue and elicits immediate activation and proliferation of resident cells, which are able to undertake repair and regeneration of structures of both mesenchymal and epithelial origin. Experimental evidence indicates that infused cells function essentially through paracrine pathways, decreasing inflammation and fibrosis. In both severe cardiac and renal disorders, cell therapies appear to be a promising therapeutic option.

show abstract

Cell transplantation for cardiac regeneration: where do we stand?

Cited by 10 publications

References 69 publications

Whole Organ Engineering: Approaches, Challenges, and Future Directions

Whole Organ Engineering: Approaches, Challenges, and Future Directions

Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results

Cardiac and renal cell therapies: similarities and differences

Contact Info

Product

Resources

About